Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 29, 2022 13:00 ET | Source: TearClear Corp.

TearClear Announces Positive Topline Results from CLEAR Phase 3 Study for the Treatment of Glaucoma with TC-002 (latanoprost ophthalmic solution 0.005%)

Successfully met the primary and all secondary endpoints On track for New Drug Application (NDA) filing, with the FDA in Q1 2023 TC-002 is the first of four proprietary glaucoma drugs in the...
February 07, 2022 05:00 ET | Source: TearClear Corp.

TearClear announces the successful initiation of its TC-002 Latanoprost Ophthalmic Solution Phase 3 trial

BOSTON, Feb. 07, 2022 (GLOBE NEWSWIRE) -- TearClear, a late clinical stage ophthalmic pharmaceutical company, is pleased to announce the TC-002 Phase 3 trial has been successfully initiated....
September 08, 2021 09:52 ET | Source: TearClear Corp.

TearClear Files Investigational New Drug (IND) Application to Begin its Clinical Trial for TC-002 Latanoprost Ophthalmic Solution, 0.005%

BOSTON, Sept. 08, 2021 (GLOBE NEWSWIRE) -- TearClear, a late clinical stage ophthalmic pharmaceutical company, has filed an Investigational New Drug (IND) application to conduct a registrational...
March 16, 2021 07:28 ET | Source: TearClear Corp.

TearClear Moving Toward Clinical Trials and Strengthening Leadership Team

BOSTON, March 16, 2021 (GLOBE NEWSWIRE) -- TearClear continues to make progress on the development of its first-in-class platform of preservative-free topical medications. With a successful Pre-IND...
December 01, 2020 06:00 ET | Source: TearClear Corp.

TearClear Announces Successful Completion of Pre-IND Meeting with the FDA for a Preservative Free Multi-Dose Delivery of Latanoprost for the Treatment of Glaucoma

BOSTON, Dec. 01, 2020 (GLOBE NEWSWIRE) -- TearClear, an emerging ophthalmic pharmaceutical company, today announced successful completion of pre-IND (Investigational New Drug) meeting with the U.S....
September 29, 2020 06:00 ET | Source: TearClear Corp.

TearClear Appoints Robert Bailey to Board of Directors

BOSTON, Sept. 29, 2020 (GLOBE NEWSWIRE) -- TearClear announces the appointment of industry veteran Robert Bailey to the company’s Board of Directors. Mr. Bailey brings over two decades of leadership...
August 11, 2020 07:00 ET | Source: TearClear Corp.

TearClear Raises $22 Million to Advance Multiple Clinical Programs in Development

BOSTON, Aug. 11, 2020 (GLOBE NEWSWIRE) -- TearClear has raised $22M in a Series B funding round. The investment will be used to advance multiple clinical programs in development, with two lead...
May 20, 2020 07:00 ET | Source: TearClear Corp.

TearClear appoints Dr. Amir Shojaei Chief Development Officer

BOSTON, May 20, 2020 (GLOBE NEWSWIRE) -- TearClear Corp., an emerging Ophthalmic Pharmaceutical Company, has announced the appointment of Amir Shojaei, Pharm.D., Ph.D., as Chief Development Officer,...
April 16, 2020 07:30 ET | Source: TearClear Corp.

TearClear appoints Robert J. Dempsey Chief Executive Officer

BOSTON, April 16, 2020 (GLOBE NEWSWIRE) -- TearClear, a global Ophthalmic Pharmaceutical Company, today announced the appointment of Robert J. Dempsey as Chief Executive Officer. TearClear is the...
May 29, 2019 08:00 ET | Source: TearClear Corp.

TearClear Appoints Chief Scientific and Innovation Officer

Industry Leader Srini Venkatesh, PhD, to drive TearClear’s scientific and R&D strategy Supports the next phase of development for its disruptive ophthalmic pharmaceutical platform ORANGE...